5、消化系统肿瘤消化系统肿瘤 (14).pdf

Journal of Clinical Oncology List of Issues Volume 39,Issue 3_suppl Meeting Abstract|2021 Gastrointestinal Cancers SymposiumHEPATOBILIARY CANCERLenvatinib plus pembrolizumab for patientswith previously treated biliary tract cancersin the multicohort phase II LEAP-005 study.Rights&PermissionsOPTIONS&TOOLSExport CitationTrack CitationAdd To FavoritesCOMPANION ARTICLESADVERTISEMENTADADVERTISEMENTLog InSubmitE-AlertsCartOpenAthens/Shibboleth MENU Article ToolsLuis Villanueva,Zarnie Lwin,Hyun Cheol Chung,Carlos Gomez-Roca,Federico Longo,Eduardo Yanez,.Show MoreAbstract Disclosures321Background:Second-line treatment options forpatients with biliary tract cancers(BTC)arelimited.Lenvatinib,an anti-angiogenic multikinaseinhibitor,in combination with the programmeddeath-1 immune checkpoint inhibitorpembrolizumab,has demonstrated promisingantitumor activity with a manageable safetyprofile in patients with select advanced solidtumors.LEAP-005(NCT03797326)is evaluating theefficacy and safety of lenvatinib pluspembrolizumab in patients with previously treatedadvanced solid tumors;here we present resultsfrom the BTC cohort of LEAP-005.Methods:In thisNo companion articlesARTICLE CITATIONDOI:10.1200/JCO.2021.39.3_suppl.321Journal of Clinical Oncology 39,no.3_suppl(January 20,2021)321-321.Published online January 22,2021.WE RECOMMENDADVERTISEMENTEmployer:Merritt HawkinsApply for this job Employer:Potomac Oncology&HematologyApply for this job Hematology-Oncology OpportunityJust Outside of ChicagoRockford,Illinois N/AA reputable integrated health system seekinga board-certified or board-eligiblehematologist-oncologist to join its team.Oncology&Hematology AssociatePositionRockville,Maryland Competitive SalaryThis position offers a competitive base salary,a comprehensive benefits package,exceptional productivity incentives,and apartnership track.Hematology/Oncology-at the Beach inLow Tax Delaware!Delaware(US);Family-oriented resort area inbeautiful south coastal DelawareAbstractPhase Ib Study of Lenvatinib PlusPembrolizumab in Patients WithUnresectable HepatocellularCarcinomaRichard S.Finn et al.,J Clin Oncol,20202018 ASCO:KEYNOTE-427 TrialEvaluates Pembrolizumab inAdvanced Clear Cell Renal CellCarcinomaBy The ASCO Post,The ASCO Post,20182018 ASCO:KEYNOTE-427 TrialEvaluates Immunotherapy inAdvanced Clear Cell Renal CellCarcinomaBy The ASCO Post et al.,KidneyCancer,2018Lenvatinib Plus Pembrolizumab inPatients With Advanced EndometrialCancerVicky Makker et al.,J Clin Oncol,2020nonrandomized,open-label,phase II study,eligible patients were aged 18 years withhistologically or cytologically documentedadvanced(metastatic and/or unresectable)BTCwith disease progression after 1 prior line oftherapy,measurable disease per RECIST v1.1,ECOG PS of 01,and tissue sample evaluable forPD-L1 expression.Patients received lenvatinib 20mg once daily plus pembrolizumab 200 mg Q3Wfor up to 35 cycles(approximately 2 years)or untilconfirmed disease progression,unacceptabletoxicity,or withdrawal of consent.Treatment withlenvatinib could continue beyond 2 years inpatients experiencing clinical benefit.Primaryendpoints were ORR(per RECIST v1.1 by blindedindependent central review)and safety.Secondaryendpoints were the disease control rate(DCR;comprising CR,PR,and SD),duration of response(DOR),PFS,and OS.Tumor imaging wasperformed Q9W from treatment initiation for 54weeks,then Q12W to week 102,and Q24Wthereafter.Results:31 patients were enrolled inthe BTC cohort(ECOG PS 1,55%;84%ex-US).As ofADVERTISEMENTOpen-Label,Single-Arm,Phase IIStudy of PembrolizumabMonotherapy as First-Line Therapy inPatients With Advanced NonClearCell Renal Cell CarcinomaDavid F.McDermott et al.,J ClinOncol,2021Pembrolizumab Plus Chemo With orWithout Bevacizumab Approved forCervical CancerBy staff,US Pharmacist,2021KEYNOTE-013 4-year follow-up ofpembrolizumab in classical Hodgkinlymphoma after brentuximabvedotin failureArmand,Blood Advances,2020FDA Approves Another Indication forPembrolizumabBy staff,US Pharmacist,2020Current and future drugcombination strategies based onprogrammed death-1/programmeddeath-ligand 1 inhibitors in non-small cell lung cancerYing Li Cheng et al.,Chinese MedicalJournal,2021Comparison and analysis of theefficacy of drug therapy for livercancerPhilippe Merle et al.,HepatomaResearch-OAE Publishing,2020Powered byApril 10,2020,median time from first dose to datacutoff(DCO)was 9.5 months(range,3.111.9),with 16 patients on treatment at DCO.There were3(10%)PRs and 18(58%)SDs.ORR was 10%(95%CI,226),and DCR was 68%(95%CI,4983).Median DOR was 5.3 months(range,2.1+to 6.2).Median PFS was 6.1 months(95%CI,2.16.4).Median OS was 8.6 months(95%CI,5.6 to NR).Treatment-related AEs occurred in 30 patients(97%),including 15(48%)who had grade 34 AEs;there were no treatment-related deaths.2(6%)discontinued treatment due to treatment-relatedAEs(myocarditis,pyrexia;n=1 each).The mostfrequent treatment-related AEs were hypertension(42%),dysphonia(39%),diarrhea(32%),fatigue(32%),and nausea(32%).14 patients(45%)hadimmune-mediated AEs and 1 patient(3%)had aninfusion-related reaction.Conclusions:Lenvatinibplus pembrolizumab demonstrated encouragingefficacy and manageable toxicity in patients withadvanced BTC who had received 1 line of priortherapy.Based on these data,enrollment in theBTC cohort has been expanded to 100 patients.Clinical trial information:NCT03797326.2021 American Society of Clinical OncologyResearch Sponsor:Merck Sharp&Dohme Corp.,a subsidiary of Merck&Co.,Inc.,Kenilworth,NJ,USA.QUICK LINKSContentNewest Articles Archive Meeting AbstractsJournal InformationAbout Editorial Roster Contact Us PermissionsResourcesAuthors Reviewers Subscribers Institutions AdvertisersSubmit Your ManuscriptSubscribe to this JournalASCO FAMILY OF SITESJournalsJournal of Clinical Oncology JCO Oncology Practice JCO Global Oncology JCO Clinical Cancer Informatics JCO Precision OncologyPublicationsASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post EducationASCO eLearning ASCO Meetings Cancer.NetOther SitesASCO.org ASCO Author Services ASCO Career Center CancerLinQ Conquer Cancer Foundation TAPUR Study American Society of Clinical Oncology2318 Mill Road,Suite 800,Alexandria,VA 22314 Terms of Use|Privacy Policy|Cookies 2021 American Society of Clinical Oncology